Real-world data suggest that, although guideline-concordant care is on the rise, many US patients with mHSPC may not receive it.

Nivolumab plus cabozantinib provides long-term benefits over sunitinib in advanced RCC, according to final results from CheckMate 9ER.

Post-transplant cyclophosphamide (PTCy) plus sirolimus and cyclosporine can improve some outcomes when compared to mycophenolate mofetil (MMF) plus sirolimus and cyclosporine as graft-vs-host disease ...

Bone marrow transplant is associated with accelerated brain aging and worse neurocognitive functioning, data suggest.

First-line cemiplimab and platinum-based chemotherapy appears to be safe and effective for patients with advanced penile carcinoma.

The combination of savolitinib and durvalumab demonstrated durable activity in a phase 2 trial of patients with papillary RCC.

Cilta-cel enables sustained MRD negativity in patients with previously treated MM, according to results from the CARTITUDE-4 trial.

Adding cabozantinib to first-line treatment with nivolumab and ipilimumab improved PFS — but not OS — in patients with RCC.

First-line treatment with enfortumab vedotin and pembrolizumab provides durable benefits over chemotherapy in advanced urothelial carcinoma.

Perioperative durvalumab improved upon neoadjuvant chemotherapy in patients with cisplatin-eligible MIBC in the NIAGARA trial.

Neoadjuvant disitamab vedotin plus perioperative toripalimab has demonstrated efficacy in patients with HER2-expressing MIBC.